Biocon Launches New Hepatitis-C Drug

  • 2:22
  • Published On: December 24, 2015
Cinema View
Embed
Kiran Mazumdar-Shaw, CMD of Biocon, said at the moment the Indian market for this new drug is approaching Rs 200 crore and it is expected to rise to Rs 500 crore.

Related Videos

Biotech Is All About Precision Medicine: Kiran Mazumdar-Shaw | Serious Business
December 23, 2023 26:50
"I Don't Worry": Kiran Shaw Assures Bright Future For 'Agniveers'
June 20, 2022 2:36
"Agniveers Will Have Distinct Advantage In Job Market": Biocon's Kiran Shaw
June 20, 2022 5:42
Glad We Are Focusing On Wellness Instead of Just Treating Illness: Kiran Mazumdar-Shaw
October 03, 2021 12:32
Equitable Access To Vaccines Important: Kiran Mazumdar Shaw
May 06, 2021 12:20
'Urban India Set For Vaccines, Rural India Getting Ready Too'
December 30, 2020 7:07
Daily Surge In Numbers Worrying: Kiran Mazumdar Shaw
August 30, 2020 9:52
"Have Added To Covid Count...": Kiran Mazumdar Shaw Tests Positive
August 18, 2020 0:15
Psoriasis Injection Okayed For COVID Treatment: Drug Controller
July 11, 2020 5:29
There Is A Need To Conduct More COVID Tests: Kiran Mazumdar-Shaw, Biocon Limited
June 14, 2020 6:12
Biocon Gets Nod To Use CytoSorb For Critical COVID-19 Patients
May 27, 2020 3:09
'Need Bold Regulatory Reforms': Kiran Mazumdar Shaw
May 14, 2020 14:55
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination